Sun’s chief Dilip Shanghvi talks about partnering intent for the firm’s GLP-1 candidate, which he hopes can complete studies in an accelerated timeframe, while legal action in the US has a cast a shadow on launch timelines of the Indian drug maker's alopecia areata treatment.
Sun Pharmaceutical Industries Ltd., is eying the partnering route as it seeks to advance into the high-profile glucagon-like peptide-1 (GLP-1) receptor agonist space, currently witnessing huge excitement as a therapeutic class for obesity.
Sun’s specialty pipeline includes a promising early stage GLP-1 receptor agonist, GL0034(utreglutide), indicated for type 2 diabetes and obesity, which...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
